Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-exploratory study of PG-011 nasal spray in moderate-to-severe seasonal allergic rhinitis
ChiCTR2400081767Phase 2Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pumecitinib in seasonal allergic rhinitis (SAR) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Change from baseline in the mean reflective total nasal symptom score over 14 days of treatment. Started Mar 2024; status: completed.
02
Drugs
pumecitinib
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on ChiCTR2400081767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081767.